Loading
A phase 2 trial of Gallium-68 DOTATATE in Breast cancer, run by Hoag Memorial Hospital Presbyterian, with a status the registry has not verified recently.
Study of Dotatate Imaging in Breast Cancer is a phase 2 interventional study registered as NCT05880394 by Hoag Memorial Hospital Presbyterian, with 30 participants planned, started 2023-01-10 and due to reach its primary completion in 2024-07-31. Interventions recorded: Gallium-68 DOTATATE, Copper-64 DOTATATE. Conditions recorded: Breast Cancer Stage IV.
Linked to the drug Gallium-68 DOTATATE because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/